MedTrace Logo

A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia

NCT03934099 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2025-12-03

Study results available
· View outcomes & findings →

Summary

The aim of this 12-week randomized multicenter double-blind parallel group placebo-controlled dose finding study is to assess the efficacy and safety of three different doses of LC350189 in subjects with hyperuricemia and a diagnosis of gout.

Conditions

  • Gout
  • Hyperuricemia

Interventions

DRUG

LC350189 formulated capsule

Xanthine Oxidase Inhibitor

DRUG

Placebo

Matching placebo

Sponsors & Collaborators

  • LG Chem

    lead INDUSTRY

Principal Investigators

  • Hyungjin Cho, MD · LG Chem, Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-02
Primary Completion
2021-05-03
Completion
2021-05-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03934099 on ClinicalTrials.gov